1.2200
22-11月-24 15:44:58
15 分の遅延
株式
+0.0300
+2.52%
本日の幅
1.1700 - 1.2300
ISIN
N/A
ソース
NASDAQ
Atossa Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer
12 6 2023 08:15:00 提供 Nasdaq GlobeNewswire
Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer
01 6 2023 08:10:00 提供 Nasdaq GlobeNewswire